FDA Clears AI-Powered Software for Thyroid Ultrasound

News
Article

Providing automated TI-RADS classifications and worksheets, the new AI-enabled software may facilitate improved efficiency with thyroid ultrasound exams.

The Food and Drug Administration (FDA) has granted 510(k) clearance for new AI-powered software geared toward thyroid ultrasound exams.

See-Mode Technologies, the developer of the software, said the software may help standardize assessment of thyroid ultrasound exams through automated TI-RADS classification of thyroid nodules. The company noted that results from a multi-reader, multi-case study demonstrated enhanced localization and characterization of thyroid nodules with adjunctive use of the AI software.

FDA Clears AI-Powered Software for Thyroid Ultrasound

The newly FDA-cleared AI software from See-Mode Technologies for thyroid ultrasound exams reportedly provides automated TI-RADS classification of thyroid nodules. (Image courtesy of Adobe Stock.)

Facilitating workflow efficiency, the software also generates automated worksheets and reportedly streamlines reporting on follow-up thyroid studies, according to See-Mode Technologies.

“By bringing AI into routine clinical practice, we aim to reduce the reporting time and inter-operator variability that exists in thyroid ultrasound,” noted Milad Mohammadzadeh, a co-founder of See-Mode Technologies.

The company added that existing CPT codes for adjunctive AI interpretation of thyroid ultrasound may be applied for use of the See-Mode Technologies software.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.